Relief Therapeutics · ISIN: CH1251125998

Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011

Relief Therapeutics Holding SA / Key word(s): Patent Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 11.02.2025 / 07:00 CET/CEST Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Patent Secures Protection for RLF-TD011 in Epidermolysi...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 11.02.2025 | 07:00
11 February 2025 07:00AM
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Relief Therapeutics Holding SA / Key word(s): Patent Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 11.02.2025 / 07:00 CET/CEST Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Patent Secures Protection for RLF-TD011 in Epidermolysi...
© EQS Newswire
11 February 2025 01:20AM
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rar...
© ACCESSWIRE
22 January 2025 07:00AM
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US 22-Jan-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Completes Strate...
© EQS Newswire
22 January 2025 01:20AM
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Sale of GOLIKE® Rights Outside the U.S. to NutrisensRelief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products GENEVA, SWITZERLAND / ACCESS Newswire / January 22, 2025 / RELIEF THERAPEUTICS Holding SA(SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering in...
© ACCESSWIRE
27 December 2024 07:00AM
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
Relief Therapeutics Holding SA / Key word(s): Merger Relief Therapeutics Provides Update on Potential Transaction with Renexxion 27.12.2024 / 07:00 CET/CEST Relief Therapeutics Provides Update on Potential Transaction with Renexxion GENEVA (DEC. 27, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY)...
© EQS Newswire
27 December 2024 01:20AM
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2024 / RELIEF THERAPEUTICS Holding SA(SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today provided an update on the potential reverse merger with Renexxion, In...
© ACCESSWIRE
16 December 2024 07:00AM
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial 16.12.2024 / 07:00 CET/CEST Relief Therapeutics Announces Final Readout of PKU GOLIKE® Clinical Trial Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PK...
© EQS Newswire
16 December 2024 01:20AM
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU PatientsResults Expected to Promote Awareness and Adoption of PKU GOLIKE ®GENEVA, SWITZERLAND / ACCESSWIRE / December 16, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF )(OTCQB:RLFTF )(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company commi...
© ACCESSWIRE
13 December 2024 11:00PM
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations 13-Dec-2024 / 23:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Fi...
© EQS Newswire
13 December 2024 05:25PM
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB QuotationGENEVA, SWITZERLAND / ACCESSWIRE / December 13, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and...
© ACCESSWIRE
11 November 2024 07:00AM
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa 11-Nov-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therape...
© EQS Newswire
11 November 2024 01:20AM
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced positive final results from its proof-of-concept, investig...
© ACCESSWIRE
04 November 2024 07:00AM
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
Relief Therapeutics Holding SA / Key word(s): Merger Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger 04-Nov-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Signs Non-Binding...
© EQS Newswire
04 November 2024 01:20AM
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it has signed a non-binding letter of intent (LOI) with Ren...
© ACCESSWIRE
29 October 2024 07:00AM
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE 29.10.2024 / 07:00 CET/CEST Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE GENEVA (OCT. 29, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, O...
© EQS Newswire
29 October 2024 02:20AM
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
GENEVA, SWITZARLAND / ACCESSWIRE / October 29, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced the publication of a Plain Language Summary in Future Rare Diseas...
© ACCESSWIRE
25 October 2024 07:00AM
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents 25-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Reports Ne...
© EQS Newswire
25 October 2024 01:20AM
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
New Study Results Indicate Superior Absorption of RLF-OD032 in Fasted State Compared to KUVAN®, Potentially Enabling Flexible Dosing Options GENEVA, SWITZERLAND / ACCESSWIRE / October 25, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innov...
© ACCESSWIRE
21 October 2024 07:00AM
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics Holding SA / Key word(s): Patent Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment 21-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcemen...
© EQS Newswire
08 October 2024 07:00AM
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa 08-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief...
© EQS Newswire
08 October 2024 01:20AM
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA, SWITZERLAND / ACCESSWIRE / October 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced promising preliminary results from its proof-of-concept, inv...
© ACCESSWIRE
04 October 2024 07:00AM
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria 04-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief T...
© EQS Newswire
04 October 2024 01:20AM
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
GENEVA, SWITZERLAND / ACCESSWIRE / October 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today reported positive topline results from its proof-of-concept clinical s...
© ACCESSWIRE
23 September 2024 07:00AM
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement 23-Sep-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces $2 Millio...
© EQS Newswire
23 September 2024 07:00AM
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement 23-Sep-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces $2 Millio...
© EQS Newswire
23 September 2024 01:20AM
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
GENEVA, SWITZERLAND / ACCESSWIRE / September 23, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it will receive a $2 million milestone payment from SWK...
© ACCESSWIRE

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.